Hepatocellular carcinoma and hepatitis B surface protein

Area of Science:

• Hepatology
• Virology
• Oncology

Background:

• Hepatocellular carcinoma (HCC) is frequently associated with Hepatitis B virus (HBV) infection.
• HBV envelope proteins, particularly preS/S mutants, play a crucial role in viral structure, life cycle, and disease progression.
• Integrated HBV sequences can lead to replication-defective, truncated, and mutated preS/S proteins, considered early indicators of HCC.

Purpose of the Study:

• To elucidate the role of HBV preS/S mutants in hepatocellular carcinoma (HCC) tumorigenesis.
• To identify novel biomarkers for HBV-associated HCC.
• To explore therapeutic strategies targeting HBV proteins and their associated damage.

Main Methods:

• Analysis of HBV preS/S mutants as "precursor lesions" in HCC development.
• Investigation of mechanisms of tumorigenesis induced by preS/S mutants, including transcription factor activation and inflammatory responses.
• Identification of preS2 mutants and "Ground Glass" hepatocytes as potential biomarkers.
• Exploration of pathways involved in preS mutant-induced endoplasmic reticulum stress.
• Review of treatments including antivirals and antioxidants.

Main Results:

• PreS/S mutants are implicated as "precursor lesions" in HCC.
• These mutants trigger tumorigenesis via mechanisms like transactivation and immune inflammation.
• PreS2 mutants and "Ground Glass" hepatocytes are identified as novel biomarkers for HBV-associated HCC.
• PreS mutants can activate unfolded protein response and endoplasmic reticulum stress pathways.

Conclusions:

• HBV preS/S mutants are critical in HBV-associated HCC development.
• PreS2 mutants and "Ground Glass" hepatocytes serve as valuable biomarkers for early detection and prognosis.
• Comprehensive treatment strategies involving antivirals and antioxidants are essential for managing HBsAg and preS/S mutant-induced damage in HCC prevention and therapy.